Oyster Point Pharma, Inc. (OYST) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET
Company Participants
Arty Ahmed – Vice President, Investor Relations
Dr. Jeffrey Nau – President and Chief Executive Officer
Dan Lochner – Chief Financial Officer and Chief Business Officer
Michael Campbell – Senior Vice President and Head of Commercial
Conference Call Participants
Patrick Dolezal – LifeSci Capital
Ken Cacciatore – Cowen
Joe Catanzaro – Piper Sandler
Daniil Gataulin – Chardan
Operator
Good day, and thank you for standing by. Welcome to the Oyster Point Pharma Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to your speaker for today, Arty Ahmed, Vice President, Investor Relations. You may begin.
Arty Ahmed
Good evening, everyone, and welcome to Oyster Point Pharma’s Second Quarter 2022 Earnings Conference Call. This evening, we issued a press release containing our financial results and recent business highlights for the second quarter ended June 30, 2022. In addition, our earnings press release and Form 10-Q, which were filed with the SEC after the close of market today, are available on our website under the Investors and Media section at www.oysterpointrx.com.
Joining us on our call today are Dr. Jeffrey Nau, the President and Chief Executive Officer of Oyster Point Pharma; Dan Lochner, our Chief Financial Officer and Chief Business Officer; and Michael Campbell, our Senior Vice President and Head of Commercial. Following our prepared remarks, we will open up the line for questions.
Please note that during the call today, we will be making forward-looking statements regarding potential future events, including statements on Oyster Point Pharma’s potential future financial status and results of operations, and our plans and